First patient enrolled in phase 2 ocriplasmin study to treat nonproliferative diabetic retinopathy

The first patient has been enrolled in the phase 2 CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment in patients with nonproliferative diabetic retinopathy, ThromboGenics announced in a press release. The randomized, double-masked, sham-controlled, multicenter study will include 230 patients with moderately severe to very severe nonproliferative diabetic retinopathy who will receive up to three intravitreal injections of 0.125 mg or 0.0625 mg of Jetrea (ocriplasmin). The duration of the study will be about 24 months for each patient from the first injection.